EX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 ASX ANNOUNCEMENT 9 April 2026 ────────────────────────────────────── EBR Reports Strong Q1 2026 Growth in Commercial Cases Key Highlights Robust commercial momentum continued through Q1 2026 with case volumes more than doubling from Q4 2025 ─────────────────────────────────────────────────────────────────────────────── The WiSE® System was successfully implanted in 41 commercial patients during the quarter, bringing total implants across the pilot phase and Limited Market Release to 71 ─────────────────────────────────────────────────────────────────────────────────────────────────────── EBR expects to report revenue in the range of US$2.25M to US$2.36M for Q1 2026, based on preliminary unaudited quarter-end results and subject to quarter-end closing adjustments The Limited Market Release continued to advance in Q1 2026 with an additional 16 purchase agreements signed and 22 additional physicians trained to support the adoption of WiSE ────────────────────────────────────────────────────────────────────────────────────────────────────── Investor webinar on Friday 10 April 2026 at 09:00am AEST ─…
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
EBR Systems, Inc.
EBRCZOTCEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On April 9, 2026 (Australia time), EBR Systems, Inc. (the “Company”) issued a press release announcing the Company’s commercial progress, as well as preliminary financial results for the first quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report.…
Company context
Silicon Valley-based EBR Systems (ASX:EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.